©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Surg. Aug 27, 2022; 14(8): 874-876
Published online Aug 27, 2022. doi: 10.4240/wjgs.v14.i8.874
Published online Aug 27, 2022. doi: 10.4240/wjgs.v14.i8.874
Risk prediction of common bile duct stone recurrence based on new common bile duct morphological subtypes
Hirokazu Saito, Shuji Tada, Department of Gastroenterology, Kumamoto City Hospital, Kumamoto 862-8505, Japan
Author contributions: Saito H wrote the letter; Tada S revised the letter.
Conflict-of-interest statement: The authors declare that there are no conflicts of interest in relation to this article.
Corresponding author: Hirokazu Saito, MD, Doctor, Department of Gastroenterology, Kumamoto City Hospital, 4-1-60, Higashimachi, Higashi-ku, Kumamoto 862-8505, Japan. arnestwest@yahoo.co.jp
Received: April 19, 2022
Peer-review started: April 19, 2022
First decision: June 12, 2022
Revised: June 16, 2022
Accepted: July 20, 2022
Article in press: July 20, 2022
Published online: August 27, 2022
Processing time: 127 Days and 4.4 Hours
Peer-review started: April 19, 2022
First decision: June 12, 2022
Revised: June 16, 2022
Accepted: July 20, 2022
Article in press: July 20, 2022
Published online: August 27, 2022
Processing time: 127 Days and 4.4 Hours
Core Tip
Core Tip: It is important to identify the risk factors associated with the recurrence of common bile duct (CBD) stones after endoscopic treatment as it helps determine the necessity of regular follow-up in patients who underwent endoscopic CBD stone removal. CBD morphology can be an important predictor of stone recurrence after endoscopic stone removal. Further studies with a large sample size and a longer follow-up period are warranted to examine the efficacy of the new CBD morphological subtypes presented by the authors for predicting endoscopic retrograde cholangiopancreatography outcomes after CBD stone removal.